Literature DB >> 22215677

Mass spectrometry-assisted study reveals that lysine residues 1967 and 1968 have opposite contribution to stability of activated factor VIII.

Esther Bloem1, Henriet Meems, Maartje van den Biggelaar, Carmen van der Zwaan, Koen Mertens, Alexander B Meijer.   

Abstract

The A2 domain rapidly dissociates from activated factor VIII (FVIIIa) resulting in a dampening of the activity of the activated factor X-generating complex. The amino acid residues that affect A2 domain dissociation are therefore critical for FVIII cofactor function. We have now employed chemical footprinting in conjunction with mass spectrometry to identify lysine residues that contribute to the stability of activated FVIII. We hypothesized that lysine residues, which are buried in FVIII and surface-exposed in dissociated activated FVIII (dis-FVIIIa), may contribute to interdomain interactions. Mass spectrometry analysis revealed that residues Lys(1967) and Lys(1968) of region Thr(1964)-Tyr(1971) are buried in FVIII and exposed to the surface in dis-FVIIIa. This result, combined with the observation that the FVIII variant K1967I is associated with hemophilia A, suggests that these residues contribute to the stability of activated FVIII. Kinetic analysis revealed that the FVIII variants K1967A and K1967I exhibit an almost normal cofactor activity. However, these variants also showed an increased loss in cofactor activity over time compared with that of FVIII WT. Remarkably, the cofactor activity of a K1968A variant was enhanced and sustained for a prolonged time relative to that of FVIII WT. Surface plasmon resonance analysis demonstrated that A2 domain dissociation from activated FVIII was reduced for K1968A and enhanced for K1967A. In conclusion, mass spectrometry analysis combined with site-directed mutagenesis studies revealed that the lysine couple Lys(1967)-Lys(1968) within region Thr(1964)-Tyr(1971) has an opposite contribution to the stability of FVIIIa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22215677      PMCID: PMC3285348          DOI: 10.1074/jbc.M111.308627

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

2.  Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.

Authors:  Jacky Chi Ki Ngo; Mingdong Huang; David A Roth; Barbara C Furie; Bruce Furie
Journal:  Structure       Date:  2008-04       Impact factor: 5.006

3.  Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation.

Authors:  Keiji Nogami; Midori Shima; Tomoko Matsumoto; Katsumi Nishiya; Ichiro Tanaka; Akira Yoshioka
Journal:  J Biol Chem       Date:  2006-12-21       Impact factor: 5.157

4.  Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.

Authors:  A J Gale; K-P Radtke; M A Cunningham; D Chamberlain; J-L Pellequer; J H Griffin
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

Review 5.  Extending half-life in coagulation factors: where do we stand?

Authors:  David Lillicrap
Journal:  Thromb Res       Date:  2008       Impact factor: 3.944

6.  Intracellular cotrafficking of factor VIII and von Willebrand factor type 2N variants to storage organelles.

Authors:  Maartje van den Biggelaar; Alexander B Meijer; Jan Voorberg; Koen Mertens
Journal:  Blood       Date:  2008-12-16       Impact factor: 22.113

7.  IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.

Authors:  Pauline M W van Helden; H Marijke van den Berg; Samantha C Gouw; Paul H P Kaijen; Marleen G Zuurveld; Evelien P Mauser-Bunschoten; Rob C Aalberse; Gestur Vidarsson; Jan Voorberg
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

8.  Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity.

Authors:  Henriët Meems; Alexander B Meijer; David B Cullinan; Koen Mertens; Gary E Gilbert
Journal:  Blood       Date:  2009-08-17       Impact factor: 22.113

9.  Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface.

Authors:  Hironao Wakabayashi; Fatbardha Varfaj; Jennifer Deangelis; Philip J Fay
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

10.  Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations.

Authors:  H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2008-12-04       Impact factor: 5.824

View more
  8 in total

1.  A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

2.  Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

Authors:  Maartje van den Biggelaar; Jesper J Madsen; Johan H Faber; Marleen G Zuurveld; Carmen van der Zwaan; Ole H Olsen; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2015-04-21       Impact factor: 5.157

3.  Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.

Authors:  Esther Bloem; Maartje van den Biggelaar; Aleksandra Wroblewska; Jan Voorberg; Johan H Faber; Marianne Kjalke; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-09-05       Impact factor: 5.157

4.  Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Authors:  M Monaghan; H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2016-03-21       Impact factor: 5.824

5.  Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.

Authors:  Lydia Castro-Núñez; Esther Bloem; Mariëtte G Boon-Spijker; Carmen van der Zwaan; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

6.  Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene.

Authors:  Tewarit Sarachana; Neetu Dahiya; Vijaya L Simhadri; Gouri Shankar Pandey; Surbhi Saini; Christine Guelcher; Michael F Guerrera; Chava Kimchi-Sarfaty; Zuben E Sauna; Chintamani D Atreya
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

7.  D' domain region Arg782-Cys799 of von Willebrand factor contributes to factor VIII binding.

Authors:  Małgorzata A Przeradzka; Josse van Galen; Eduard H T M Ebberink; Arie J Hoogendijk; Carmen van der Zwaan; Koen Mertens; Maartje van den Biggelaar; Alexander B Meijer
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

8.  SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.

Authors:  Kenneth C Childers; Shaun C Peters; Pete Lollar; Harold Trent Spencer; Christopher B Doering; Paul C Spiegel
Journal:  Blood Adv       Date:  2022-06-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.